Central Drugs Compounding Pharmacy Revenue and Competitors
Estimated Revenue & Valuation
- Central Drugs Compounding Pharmacy's estimated annual revenue is currently $11.5M per year.
- Central Drugs Compounding Pharmacy's estimated revenue per employee is $201,000
Employee Data
- Central Drugs Compounding Pharmacy has 57 Employees.
- Central Drugs Compounding Pharmacy grew their employee count by 6% last year.
Central Drugs Compounding Pharmacy's People
Name | Title | Email/Phone |
---|
Central Drugs Compounding Pharmacy Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Central Drugs Compounding Pharmacy?
Central Drugs Compounding Pharmacy is a leading compounding pharmacy dedicated to providing innovative products and comprehensive services to physicians, clinics and their patients in the areas of BHRT, IV Nutrition Therapy, Urology, Weight Loss, Pain Management, Dermatology, and more. With online services and two Southern California locations in Fullerton and La Habra, Central Drugs is passionate about bringing the best in custom solutions, quality products, and customer service since 1999. Our experienced and knowledgeable pharmacists provide the education and resources to promote healthy lives for patients across the country.
keywords:N/AN/A
Total Funding
57
Number of Employees
$11.5M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $16M | 66 | 2% | N/A |
#2 | $35M | 90 | -5% | N/A |
#3 | $45.5M | 129 | 34% | N/A |
#4 | $50.4M | 202 | 5% | N/A |
#5 | $70M | 311 | 1% | N/A |